A novel radiopharmaceutical probe developed at Massachusetts General Hospital (MGH) has the potential of providing physicians with information that could save the lives of patients with ischemic stroke or pulmonary embolism. Both conditions are caused when important blood vessels are blocked by a clot that has traveled from another part of the body. In a report that will appear in the October issue of the journal Arteriosclerosis, Thrombosis and Vascular Biology and has been published online, the MGH team describes using this new probe to conduct full-body scans in an animal model. Preliminary results also were reported earlier this year at the national meeting of the American Chemical Society.

3-D tomosynthesis is the latest technology to provide clearer images during screening and diagnostic procedures; however, it has not always been widely available. Hologic was the only vendor with U.S. Food and Drug Administration (FDA) approval until April of this year, when Siemens received the much-awaited green light to sell their product in the United States. In the KLAS report Women's Imaging 2015: Are New Technologies Delivering Promised Benefits?, data shows Hologic is still dominating the 3-D tomosynthesis marketplace but is facing competition from Siemens and GE. Now approved, Siemens did not waste any time upgrading their systems, and providers are responding positively. GE is not receiving the same response from users because their 3-D system is lagging due to implementation delays.

Hitachi Ltd. announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for commercial supply of the new Probeat-V system designed and developed for Mayo Clinic in Rochester, Minnesota. Treatments began in late June and the first patient treatment was completed in August 2015.

September 15, 2015 — Imaging patients soon after a traumatic brain injury (TBI) can lead to more accurate detection of ...

September 14, 2015 — A new decision rule will help emergency department physicians determine when to use radiography in ...

ImaginAb Inc. has released interim results from a Phase 2 clinical trial of IAB2M, the company's proprietary imaging agent for management of prostate cancer. IAB2M demonstrated superior performance in detecting disease compared with ProstaScint and conventional imaging technologies including computed tomography (CT) scans, magnetic resonance imaging (MRI) scans and bone scans. In addition, the agent accurately detected metastatic disease in normal-sized lymph nodes, overcoming a major limitation of existing technologies and addressing a key clinical need.

September 14, 2015 — University of Arkansas for Medical Sciences (UAMS) researcher Vladimir Zharov, Ph.D., D.Sc., was ...